Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | SMPD3 | Q9NY59 | 2/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9911040 | 0.80 | KDM4E (0.41) | SMPD3CDK2AXLIRAK4KDM4E | |
| SCHEMBL9934113 | 0.77 | SMPD3 (0.35) | SMPD3CDK2AXLTP53IRAK4 | |
| SCHEMBL19155876 | 0.76 | NPC1 (0.35) | SMPD3CDK2AXLHTR2AHTR2C | |
| SCHEMBL19772846 | 0.76 | GABRA1 (0.40) | GABRA1GABRB2TP53ADRA2CHTR2A | |
| SCHEMBL14667001 | 0.73 | SMPD3 (0.36) | GABRA1GABRB2SMPD3CDK2AXL | |
| SCHEMBL9124027 | 0.70 | SMPD3 (0.39) | SMPD3CDK2AXLIRAK4KDM4E | |
| SCHEMBL9924212 | 0.69 | SMPD3 (0.36) | SMPD3CDK2AXLKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL31619326 | 0.68 | SMPD3 (0.38) | SMPD3CDK2AXLIRAK4KDM4E | |
| SCHEMBL19155604 | 0.68 | SMPD3 (0.33) | SMPD3AXLALDH1A1 | |
| SCHEMBL19574790 | 0.67 | GABRA1 (0.37) | GABRA1GABRB2TLR7ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10703764-B2 | Benzopiperazine compositions as BET bromodomain inhibitors | FORMA THERAPEUTICS, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190330233-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330233-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRPF3, BRD7 | GABRA1 810/4885GABRB2 675/4885SMPD3 4266/4885 |
| US-10703764-B2 | Benzopiperazine compositions as BET bromodomain inhibitors | BRD4, BRPF3, BRD7 | GABRA1 810/4885GABRB2 675/4885SMPD3 4266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.